OR WAIT 15 SECS
GE Healthcare Life Sciences and Guangzhou Development District Investment Promotion Bureau have signed an agreement to jointly establish a training center for biopharmaceutical professionals.
According to a Dec. 4, 2019 press release, GE Healthcare Life Sciences and Guangzhou Development District Investment Promotion Bureau (GDD) have signed an agreement to jointly establish a training center for biopharmaceutical professionals.
The Guangzhou Bioprocess Academy will provide single-use bioprocessing training, aligned with good manufacturing practices (GMP) standards, for the latest biologic drug production processes. Delivery of the educational courses will be supported by GE Healthcare, which will also provide the single-use equipment.
“Guangdong is a strategic center for the development of China's biopharmaceutical industry,” said Emmanuel Ligner, president and CEO of GE Healthcare Life Sciences, in the press release. “This investment cooperation with GDD on professional training in the biopharmaceutical field is a new milestone in our continued investment in the China market and another way we fully support the development of the Chinese biopharmaceutical industry.”
“As a long-term partner of Chinese pharmaceutical enterprises, GE Healthcare Life Sciences has strong product lines, as well as the experience and expertise in biotechnology R&D, biopharmaceutical production and management training,” added Yu Lihua, general manager of GE Healthcare Life Science China, in the press release. “We are eager to collaborate with the government and the industry to build more professional and mature talent training bases, with this academy as a model, and support the growth of local talents.”
The Guangzhou BioProcess Academy is expected to open in September 2020 and there are plans for the academy to nurture collaborations with universities in the region so that an academic course on biomanufacturing can be developed in the future to encompass theory and practical learning.
Source: GE Healthcare